Pasithea Therapeutics CORP. (KTTAW) — 10-Q Filings

10-Q Filings (6)

• Pasithea's Cash Dwindles Amid Rising Losses, Clinical Trials Advance — Nov 13, 2025 Risk: high
  Pasithea Therapeutics Corp. (KTTAW) reported a net loss of $3.04 million for the three months ended September 30, 2025, a slight increase from $3.00 million in
• Pasithea Narrows Losses, Boosts Cash Amidst Going Concern Warning — Aug 14, 2025 Risk: high
  Pasithea Therapeutics Corp. (KTTAW) reported a net loss of $3,716,157 for the three months ended June 30, 2025, a decrease from $3,866,249 in the same period of
• Pasithea Therapeutics Files Q1 2025 10-Q — May 15, 2025 Risk: low
  Pasithea Therapeutics Corp. filed its 10-Q for the quarterly period ended March 31, 2025. The company, incorporated in Delaware with its principal executive off
• Pasithea Therapeutics Files Q3 2024 10-Q — Nov 13, 2024 Risk: low
  Pasithea Therapeutics Corp. filed its 10-Q for the quarterly period ended September 30, 2024. The company, incorporated in Delaware, operates in the Pharmaceuti
• Pasithea Therapeutics Files Q2 2024 10-Q — Aug 13, 2024 Risk: medium
  Pasithea Therapeutics Corp. filed its 10-Q for the quarterly period ended June 30, 2024. The company, incorporated in Delaware, is in the pharmaceutical prepara
• Pasithea Therapeutics Corp. Files 10-Q for Period Ended March 31, 2024 — May 14, 2024 Risk: low
  Pasithea Therapeutics Corp. (KTTAW) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Pasithea Therapeutics Corp. filed a 10-Q report for the quarte

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX